

Title: Antisense Oligonucleotide (ASO)-Based Therapies - 8/29/2025

Program Goal: 1 Describe several FDA-approved antisense oligonucleotide (ASO) therapies

2 Describe two mechanisms that ASOs can be used to modulate their targets

Target Audience: Cardiology, Endocrinology, Gastroenterology, Hematology, Internal Medicine, Nephrology, Pulmonary Medicine, Rheumatology, Sleep Medicine, Geriatrics, Critical Care, Oncologist, Hepatologist

Faculty: